ReviewThrombosis journal2026
A scoping review of factors affecting activated clotting time measurement results.
Review in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActivated clotting time (ACT), a widely used point-of-care test, monitors anticoagulation in clinical settings. Despite ACT technology advancements, some uncertainties remain regarding the factors influencing ACT measurements and inter-device variability. Although ACT is widely used for anticoagulation monitoring in clinical practice, the factors affecting ACT values are not fully understood, complicating their interpretation. This scoping review aims to address these challenges by examining the factors affecting ACT measurements, highlighting gaps in current knowledge.
methodsA systematic search was conducted in MEDLINE (PubMed), including animal studies, clinical trials, observational studies, in vitro experiments, and systematic reviews. Article selection involved a two-step process: initial title and abstract screening followed by a full-text review, this was performed by three independent reviewers. Data from the included studies were charted and extracted, collecting information on factors influencing ACT measurements.
resultsA total of 1908 records were identified, with 74 studies included after screening. Key factors influencing ACT measurements included platelet count, platelet inhibitors, and hematocrit levels. Direct thrombin inhibitors, low-molecular-weight heparin, and direct oral anticoagulants prolonged ACT with characteristics different from heparin. Aprotinin and nafamostat mesylate interacted with coagulation activators during ACT measurements affecting results. Significant differences in ACT measurements were observed between devices.
conclusionsThis scoping review comprehensively analyzed factors influencing ACT and emphasized ACT measurement variability across devices. Despite its widespread use as a point-of-care test for anticoagulation monitoring, ACT's limitations and device discrepancies highlight the need for cautious interpretation in clinical settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.